By John Vandermosten, CFA
NASDAQ:BLRX
READ THE FULL BLRX RESEARCH REPORT
We are initiating on BioLineRx Ltd. (NASDAQ:BLRX) with our valuation based on the companys progress advancing Motixafortide for the mobilization of hematopoietic stem cells (HSCs) for autologous transplantation in subjects with multiple myeloma (MM). Pivotal trials for this indication have been completed, a pre-new drug application (NDA) meeting has been conducted and an NDA submission is planned for 1H:22. The companys main area of research and innovation targets various solid and hematopoietic malignancies. The late clinical-stage biopharmaceutical company has in-licensed two compounds that are in various stages of development. The most advanced candidate is Motixafortide for stem cell mobilization. It has completed Phase III and pharmacoeconomic studies and trial data is being compiled to go before the FDA for approval. Other programs are in Phase II or earlier development for specific cancer indications.
BioLineRx is developing two candidates. The first, Motixafortide, or BL-8040, has successfully completed a Phase III study in stem cell mobilization for multiple myeloma patients and is targeting NDA submission in 1H:22. The drug is also in development for metastatic pancreatic cancer and other solid tumors, and acute myeloid leukemia (AML). The second candidate in the portfolio is AGI-134, a synthetic -Gal glycolipid that is being investigated for the treatment of solid tumors.
BioLineRx aims to provide a new standard of care treatment option for autologous bone marrow transplantation in patients with various hematological malignancies using Motixafortide. Top-line results from the GENESIS trial demonstrated a 3.5-fold increase in achieving target stem cell mobilization in two apheresis sessions for Motixafortide and granulocyte-colony stimulating factor (G-CSF) vs. G-CSF alone. The combination investigational treatment yielded more CD34+ stem cells to be mobilized in less time, with equal engraftment efficacy, safety, and tolerability, and in fewer leukapheresis sessions compared with standard of care (SoC) alone. The candidate molecule has demonstrated measurable clinical, pharmacological and cost reduction benefits.
Story continues
We anticipate a near term submission of a new drug application (NDA) to the FDA and marketing authorization application (MAA) to the EMA. Following what we anticipate to be a normal review period, commercialization of Motixafortide is expected in 2023 in the United States, with Europe to follow twelve to eighteen months thereafter, if approved. There are over 70,000 stem cell transplants in the US and Europe each year for blood cancers of which approximately 45,000 are autologous. The strong evidence for high mobilization yield of Motixafortide as monotherapy and in combination with G-CSF supports high penetration into stem cell transplant procedures.
Motixafortide is also being evaluated in pancreatic cancer. The drug attracts immune cells into the tumor microenvironment and induces T cell infiltration turning a tumor hot, thereby giving checkpoint inhibitors room to work. Motixafortide has completed a Phase IIa program with pembrolizumab and chemotherapy targeting metastatic pancreatic cancer.
BioLineRx second candidate is AGI-134, a glycolipid-like small molecule that coats tumor cells with xenoantigen Gal1-3Gal1-4GIcNAc (-Gal) in situ. Drug administration leads to opsonization, essentially tagging a pathogen for immune destruction by antibodies, utilizing pre-existing, natural anti--Gal antibodies which trigger T-cell mediated anti-tumoral immunity. This asset is in a Phase I/IIa study for solid tumors and is expected to provide a read out in the first half of 2022.
In our initiation, we provide a scientific background on cytokines and their various receptors, including CXCR4, which is implicated in the mobilization of hematopoietic stem cells. Background on chemokine agonists available in the market and in advanced studies is offered. We discuss stem cell transplantation and its relevant statistics. The report then moves into a review of BioLineRx clinical candidates: Motixafortide and AGI-134. Mechanism of action is detailed and clinical trials both completed and active are examined for each indication. Epidemiology and standard of care treatment are presented for MM, AML along with additional details for pancreatic cancer. A review of the companys intellectual property is followed by an exposition on the competitive environment and management profiles. We conclude with a summary of recent financial and operational events, risks and our valuation assumptions.
Key reasons to own BLRX shares:
Motixafortide is an advanced candidate in multiple indications
Completed Phase III clinical trial for stem cell mobilization
Active pancreatic cancer program has completed Phase IIa
Motixafortide provides material improvement over primary therapy in HSCT
3.5x more effective vs. SoC for mobilization in primary endpoint
9.3x more effective vs. SoC for mobilizing >6 million cells in one apheresis session
Almost 90% of patients advanced to transplantation after one apheresis session
Greater cell collection after apheresis allowing for second HSCT if needed
Compelling economic and safety rationale for Motixafortide
Superior efficacy
Fewer apheresis sessions reduce infection risk & hospital bed demand
NDA submission for Motixafortide in stem cell mobilization expected in 1H:22
Motixafortide & anti-PD-1 combination seeking partner for Phase IIb in pancreatic cancer
Combination study may initiate in next 12 months
Phase I/IIa AGI-134 in development for solid tumors
SUBSCRIBE TO ZACKS SMALL CAP RESEARCHtoreceive our articles and reports emailed directly to you each morning. Please visit ourwebsitefor additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.
More:
BLRX: Initiating on BioLineRx: Mobilizing the Troops with Motixafortide - Yahoo Finance
- 100 plus years of stem cell research20 years of ISSCR - PMC - March 26th, 2024
- Stem Cell Science and Human Research Studies Ahead of Cargo Arrival - NASA Blogs - February 18th, 2024
- Stem cell research project to launch into space - Fox Weather - January 24th, 2024
- Breakthrough in cancer research opening up stem cell therapy to more people. How you can get involved - 69News WFMZ-TV - January 20th, 2024
- Stem Cell Research Heading to the ISS on Axiom Mission 3 - ISS National Lab - January 18th, 2024
- No, Rep. Steve Scalise Didn't Vote Against Stem Cell Research From Which He Is Now Benefiting - The Dispatch - January 12th, 2024
- Applications are open for the Maryland Stem Cell Research Fund - Technical.ly - January 4th, 2024
- Global Stem Cell Therapy Market to Reach USD 928.6 Million by 2031: Says Allied Market Research - Yahoo Finance - November 19th, 2023
- Current state of stem cell-based therapies: an overview - PMC - November 3rd, 2023
- Dynamic Stem Cell Therapy Uncovers Research in Advance Regenrative Medicine - Yahoo Finance - November 3rd, 2023
- Research Fellow (Aging and Cancer Stem Cell Laboratory ... - Times Higher Education - October 15th, 2023
- Qkine Collaborates with the Cambridge Stem Cell Institute to Facilitate Same-Day Access to Key Research Products for Researchers at the Cambridge... - September 27th, 2023
- Stem cells: a comprehensive review of origins and emerging clinical ... - September 25th, 2023
- Stem Cell Research and Communicating Science | GBH - GBH News - September 20th, 2023
- Stem cell research reveals the earliest stages of a human life - SBS News - September 10th, 2023
- Stem Cell Therapy Market Size 2023 | Innovative Research Methodologies with Emerging Trends and Opportuni - Benzinga - September 10th, 2023
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market Research, Current Trends, Key Industry Play - Benzinga - September 8th, 2023
- Stem Cell Therapy Market 2023 Business Statistics and Research ... - The Knox Student - August 28th, 2023
- Autologous Stem Cell Based Therapies Market Analysis, Research ... - Chatfield News-Record - July 19th, 2023
- Global Stem Cell Market Projected to Reach $14 Bn by 2028: Ken Research - Yahoo Finance - July 11th, 2023
- Theradaptive Awarded Manufacturing Assistance Grant by the Maryland Stem Cell Research Fund - Benzinga - July 10th, 2023
- Bionano Announces Presentation of OGM Utility Across Stem Cell Therapy Applications at the International Society for Stem Cell Research (ISSCR) Annual... - June 19th, 2023
- Sana Biotechnology Highlights Preclinical Data from Hypoimmune and Fusogen Platforms at the International Society for Stem Cell Research (ISSCR) 2023... - June 17th, 2023
- Induced Pluripotent Stem Cell (iPSC) Global Market Report 2023: Effective Research Programs Hold Key in Roll Out of Advanced iPSC Treatments - Yahoo... - June 17th, 2023
- Lung and heart stem cell research paves way for new COVID-19 treatments - Medical Xpress - June 14th, 2023
- Toxicology PhD student cultivating giant leaps in stem cell research ... - June 4th, 2023
- Harvard Stem Cell Institute (HSCI) - May 26th, 2023
- Findings may lead to improved insulin-secreting cells derived from stem ... - May 26th, 2023
- Cell Press: Stem Cell Reports - May 26th, 2023
- Stem cell research could enable blood to be made in other parts of the body - Medical Xpress - May 26th, 2023
- Construction of myocardial patch with mesenchymal stem cells and poly ... - May 22nd, 2023
- Cedars-Sinai to Send Stem Cells to the Space Station to Aid in the ... - May 22nd, 2023
- researchers expand human blood stem cells | Institute for Stem Cell ... - May 22nd, 2023
- A Look Inside Stem Cells Helps Create Personalized Regenerative ... - May 17th, 2023
- Exclusive Research Report on Msenchymal Stem Cell and Exosome Diagnostics and Therapies Market to Witness Comp - openPR - May 17th, 2023
- The Future of Stem Cell Research: Master of Science in ... - The Daily | Case Western Reserve University - May 10th, 2023
- Exclusive Research Report on Stem Cell Therapy for Diabetes and ... - Digital Journal - May 9th, 2023
- Aging melanocyte stem cells and gray hair | National Institutes of ... - May 5th, 2023
- Mouse hair turns gray when certain stem cells get stuck - May 5th, 2023
- Science-First Skincare Company Michal Morrison Secures Exclusive World-Wide License of Proprietary STEM6 Molecule, Supported by Over 25 Years of... - May 5th, 2023
- BioCentriq and panCELLa execute research agreement to study stem cell-derived Natural Killer cell expansi - Benzinga - May 3rd, 2023
- Hair turning gray? Study finds a stem cell 'glitch' may be the cause - May 1st, 2023
- Elevai Labs Announces Research Grant Award and Partnership to Better Characterize the 'Payload' of ELEVAI's Stem Cell-derived Exosomes - Yahoo Finance - April 27th, 2023
- Why does hair turn gray? A new study says 'stuck' stem cells may ... - NPR - April 27th, 2023
- Study advances understanding of how melanocyte stem cells work to color ... - April 21st, 2023
- Stem cell research and therapy legislation to be replaced, says ... - Bahamas Tribune - April 21st, 2023
- Stem Cell Research (journal) - Wikipedia - April 21st, 2023
- Scientists Are About to Try to Create Stem Cells in Space - April 21st, 2023
- Stem Cell Research & Therapy | Articles - BioMed Central - April 16th, 2023
- Stem Cell Junk Yards Reveal a New Clue About Aging | WIRED - April 16th, 2023
- Global Stem Cells Market Research Report 2023: Implications - April 16th, 2023
- Stem cell research can help people with hard- | EurekAlert! - April 16th, 2023
- University Of Edinburgh's stem cell research gets funding boost - India Education Diary - April 14th, 2023
- Two major stem cell research projects supported with more than ... - University of California, Santa Cruz - April 8th, 2023
- Cancer detection predicts tumors before they form: discovery - March 29th, 2023
- Stem cell therapy: a potential cure for hearing loss? - March 29th, 2023
- Turkey's Only Stem Cell Production Application and Research Center - Expat Guide Turkey - March 24th, 2023
- Stem Cell Research Article, Embryonic Cells Information, Cell Therapy ... - March 24th, 2023
- Scientists create mice with cells from 2 males for 1st time - March 19th, 2023
- QBRI concludes stem cells symposium - Gulf Times - March 17th, 2023
- 2020 California Proposition 14 - Wikipedia - March 17th, 2023
- Stem Cell Reports | Journal | ScienceDirect.com by Elsevier - March 17th, 2023
- Stem cell therapy MSC-NP found to ease inflammatory activity of brain ... - March 12th, 2023
- Stem Cell Research | Office of Research Compliance | SIU - March 12th, 2023
- Heart disease study shows hope for stem cell treatment - March 4th, 2023
- Stem cells drive antler regeneration | Science - March 4th, 2023
- Stem Cell Research: Argumentative Essay - Free Essay Example - Edubirdie - March 4th, 2023
- Stem Cell Research | Thermo Fisher Scientific - US - March 4th, 2023
- Stem cell controversy - Wikipedia - February 28th, 2023
- National Institutes of Health grant funds interdisciplinary ... - February 27th, 2023
- Research Associate in Cancer Stem Cell Research job with ... - Times Higher Education - February 25th, 2023
- Pioneering Stem Cell Research Conference at The Aga Khan ... - The Aga Khan University - February 25th, 2023
- Scientists grapple with ethics of stem cell research - STAT - February 17th, 2023
- Research Associate in Stem Cell Neurobiology job with KINGS ... - Times Higher Education - January 30th, 2023
- Stem cells: past, present, and future | Stem Cell Research & Therapy ... - January 12th, 2023
- Edu Thesis & Essay: Stem cell research outline top writers online! - January 12th, 2023
- Stem Cell Biology Research Program | Johns Hopkins Institute for Cell ... - January 5th, 2023
- Stem cell population identified is vital for bone regeneration: Research - ThePrint - January 5th, 2023
- Leading scientist 'blown away' by UAE advances in stem cell research - The National - December 15th, 2022
- The Stem Cell Assay Market Is Set To Grow At A 20% Annual Rate, Due To The High Prevalence Of Chronic Diseases As Per The Business Research Company's... - December 13th, 2022
Recent Comments